Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets
OBJECTIVES: To examine the prevalence and treatment utilization of patients diagnosed with Depression and Anxiety Disorders (DAD) based on Kentucky Medicaid 2012–2019 datasets. METHODS: The study was based on Kentucky Medicaid claims data from 2012 through 2019 for patients 14 years and older. We co...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427139/ https://www.ncbi.nlm.nih.gov/pubmed/37583369 |
_version_ | 1785090168737234944 |
---|---|
author | Han, Yuchen Huang, Haojiang Mitra, Riten Hu, Huirong Pal, Subhadip McClain, Craig J Kulasekera, K.B. Kong, Maiying |
author_facet | Han, Yuchen Huang, Haojiang Mitra, Riten Hu, Huirong Pal, Subhadip McClain, Craig J Kulasekera, K.B. Kong, Maiying |
author_sort | Han, Yuchen |
collection | PubMed |
description | OBJECTIVES: To examine the prevalence and treatment utilization of patients diagnosed with Depression and Anxiety Disorders (DAD) based on Kentucky Medicaid 2012–2019 datasets. METHODS: The study was based on Kentucky Medicaid claims data from 2012 through 2019 for patients 14 years and older. We constructed yearly patient-level databases using ICD_9 CM and ICD_10 CM codes to identify the patients with DAD, using the Current Procedure Terminology (CPT) codes to identify individual psychotherapy and group psychotherapy and using the National drug codes to categorize pharmacotherapy. Based on these data, we constructed summary tables that reflected the trends in prevalence of DAD across eight Kentucky Medicaid regions and for different demographic subgroups. Next, we implemented logistic regression on the constructed yearly patient-level data to formally assess the impact of risk factors and treatments on the prevalence of DAD. The potential risk factors included age, gender, race/ethnicity, geographic characteristics, comorbidities such as alcohol use disorder and tobacco use. RESULTS: The prevalence of DAD increased from 30.84% in 2012 to 36.04% in 2019. The prevalence of DAD was significantly higher in patients with the following characteristics: non-Hispanic white, females, aged between 45 and 54 years old, living in rural areas, having alcohol use disorder, and using tobaccos. Other than 2013, the utilization of pharmacotherapy maintained at about 62%. The utilization of psychotherapy increased over years from 24.4% in 2012 to 36.5% in 2019. Overall, the utilization of any treatment slightly increased from 70.9% in 2012 to 73.3% in 2019 except a drastic decline in 2013 due to the reduction of benzodiazepine prescription. Patients being whites, females, and living in rural areas were more likely to use pharmacotherapy, and patients living in rural areas were less likely to use psychotherapy than those residing in urban areas. CONCLUSION: The prevalence of DAD has increased over time from 2012 to 2019. The utilization of pharmacotherapy maintained at 62% over eight years except 2013, and the utilization of psychotherapy has steadily increased over time. |
format | Online Article Text |
id | pubmed-10427139 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
record_format | MEDLINE/PubMed |
spelling | pubmed-104271392023-08-15 Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets Han, Yuchen Huang, Haojiang Mitra, Riten Hu, Huirong Pal, Subhadip McClain, Craig J Kulasekera, K.B. Kong, Maiying J Depress Anxiety Article OBJECTIVES: To examine the prevalence and treatment utilization of patients diagnosed with Depression and Anxiety Disorders (DAD) based on Kentucky Medicaid 2012–2019 datasets. METHODS: The study was based on Kentucky Medicaid claims data from 2012 through 2019 for patients 14 years and older. We constructed yearly patient-level databases using ICD_9 CM and ICD_10 CM codes to identify the patients with DAD, using the Current Procedure Terminology (CPT) codes to identify individual psychotherapy and group psychotherapy and using the National drug codes to categorize pharmacotherapy. Based on these data, we constructed summary tables that reflected the trends in prevalence of DAD across eight Kentucky Medicaid regions and for different demographic subgroups. Next, we implemented logistic regression on the constructed yearly patient-level data to formally assess the impact of risk factors and treatments on the prevalence of DAD. The potential risk factors included age, gender, race/ethnicity, geographic characteristics, comorbidities such as alcohol use disorder and tobacco use. RESULTS: The prevalence of DAD increased from 30.84% in 2012 to 36.04% in 2019. The prevalence of DAD was significantly higher in patients with the following characteristics: non-Hispanic white, females, aged between 45 and 54 years old, living in rural areas, having alcohol use disorder, and using tobaccos. Other than 2013, the utilization of pharmacotherapy maintained at about 62%. The utilization of psychotherapy increased over years from 24.4% in 2012 to 36.5% in 2019. Overall, the utilization of any treatment slightly increased from 70.9% in 2012 to 73.3% in 2019 except a drastic decline in 2013 due to the reduction of benzodiazepine prescription. Patients being whites, females, and living in rural areas were more likely to use pharmacotherapy, and patients living in rural areas were less likely to use psychotherapy than those residing in urban areas. CONCLUSION: The prevalence of DAD has increased over time from 2012 to 2019. The utilization of pharmacotherapy maintained at 62% over eight years except 2013, and the utilization of psychotherapy has steadily increased over time. 2022 2022-06-30 /pmc/articles/PMC10427139/ /pubmed/37583369 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution (https://creativecommons.org/licenses/by/4.0/) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Article Han, Yuchen Huang, Haojiang Mitra, Riten Hu, Huirong Pal, Subhadip McClain, Craig J Kulasekera, K.B. Kong, Maiying Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title | Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title_full | Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title_fullStr | Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title_full_unstemmed | Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title_short | Prevalence and Treatment Utilization of Patients Diagnosed with Depression and Anxiety Disorders Based on Kentucky Medicaid 2012–2019 Datasets |
title_sort | prevalence and treatment utilization of patients diagnosed with depression and anxiety disorders based on kentucky medicaid 2012–2019 datasets |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10427139/ https://www.ncbi.nlm.nih.gov/pubmed/37583369 |
work_keys_str_mv | AT hanyuchen prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT huanghaojiang prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT mitrariten prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT huhuirong prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT palsubhadip prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT mcclaincraigj prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT kulasekerakb prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets AT kongmaiying prevalenceandtreatmentutilizationofpatientsdiagnosedwithdepressionandanxietydisordersbasedonkentuckymedicaid20122019datasets |